On Thursday, Seers, a leading wearable artificial intelligence (AI) diagnostics monitoring company, announced a groundbreaking achievement. Their newly developed AI solution for precisely detecting abnormal event signals in hospitalized patients’ vital sign monitoring has been accepted at International Conference on Learning Representations (ICLR) 2026, one of the world’s most prestigious AI academic conferences.
In this pioneering study, Seers introduced an innovative AI framework. This advanced system not only classifies anomalies in real-time vital sign data, including electrocardiograms, but also accurately pinpoints the types and occurrence intervals of these events.
The research findings demonstrated the technology’s superior performance across various time-series datasets, including arrhythmia detection, emotion recognition, and human activity monitoring. Notably, it significantly enhances the potential for clinical application by accurately identifying medically significant abnormal signals, moving beyond mere anomaly detection.
This breakthrough also paves the way for enhancing AI alarms in Seers’s cutting-edge inpatient monitoring platform, thynC™.
ThynC revolutionizes patient care by leveraging AI analysis to detect real-time changes in patient conditions and promptly alert medical staff to abnormal signals.
The technology’s enhanced ability to detect rare abnormal signals is expected to improve early warning systems and increase alarm accuracy, thereby advancing thynC’s AI-driven clinical decision support capabilities.
To bolster its AI-based diagnostic and monitoring technologies, Seers has amassed an impressive portfolio of over 120 domestic and international patents, along with numerous clinical studies and academic papers. The company is continuously refining its AI prediction, analysis, and decision support technologies by harnessing the vast medical data collected through thynC and Mobicare.
Seers is rapidly evolving into a pioneering medical AI platform that bridges diagnostics and monitoring while building a robust portfolio of proprietary AI technology assets.
Dr. Hee-seok Song, Chief Technology Officer (CTO) and Vice President of Seers, emphasized that this research capitalizes on the extensive data assets and clinical expertise. It has immense potential for AI-driven clinical decision-making in hospital wards. It remains committed to strengthening the core AI technology and expanding the suite of time-series data-based AI services.
The name Seers embodies the concept of being a trailblazer. It reflects the company’s founding vision of proactively anticipating healthcare trends and developing innovative medical systems, even before digital healthcare became mainstream.